Alagille Syndrome

Alagille syndrome is a rare genetic condition that can affect multiple parts of the body, most notably the liver and the heart. In people with this syndrome, the liver has fewer bile ducts than normal. Bile ducts are tubes that carry bile, a fluid that helps digest fats, from the liver to the gallbladder and small intestine. Because there are too few of these ducts, bile builds up in the liver, causing liver damage, yellowing of the skin and eyes (jaundice), and severe itching. The condition can also affect the eyes, though it usually does not cause severe vision loss. The most common eye feature is a harmless ring in the cornea called posterior embryotoxon, which a doctor can see during an eye exam. Some patients may also have changes in the retina or optic nerve. Additionally, Alagille syndrome can cause heart defects, kidney problems, differences in the bones of the spine, and distinct facial features like a broad forehead and a pointed chin. Because the symptoms can vary widely from person to person, even within the same family, treatment is tailored to each individual's specific needs. Management often involves a team of specialists to help with liver function, nutrition, and heart health. While there is no cure yet, treatments are available to help manage symptoms, improve bile flow, and ensure patients get the right nutrients to grow and thrive.

Condition category: Syndromic IRD

Prevalence: 1 in 30,000 to 1 in 100,000

Inheritance patterns: Autosomal Dominant

Age of onset: Birth to early childhood

Clinical overview: Alagille syndrome (ALGS) is a complex, multisystem, autosomal dominant disorder characterized by a wide spectrum of clinical variability. The hallmark of the disease is a paucity of intrahepatic bile ducts, leading to chronic cholestasis. However, the syndrome is defined by involvement across multiple organ systems, with seven major clinical features: hepatic abnormalities, cardiac defects, renal dysfunction, skeletal abnormalities, ophthalmic findings, characteristic facial features, and vascular anomalies. Hepatic manifestations range from asymptomatic liver enzyme elevations to severe neonatal cholestasis, pruritus, xanthomas, and end-stage liver disease. Cardiac involvement is seen in over 90% of patients, most commonly presenting as peripheral pulmonary stenosis or tetralogy of Fallot. Ophthalmic findings are frequent, with posterior embryotoxon being the most common, though typically not affecting visual acuity. Other ocular manifestations can include optic disc anomalies and chorioretinal changes. Skeletal anomalies often include butterfly vertebrae. The characteristic facial phenotype features a broad forehead, deep-set eyes, pointed chin, and a bulbous nasal tip. The clinical presentation is highly variable, even among family members sharing the same genetic mutation. Some individuals may present with isolated features, such as cardiac or vascular anomalies, without significant liver disease. Diagnosis relies on clinical criteria and can be confirmed by genetic testing identifying mutations in the JAG1 or NOTCH2 genes, which are integral to the Notch signaling pathway essential for embryonic development.

Patient and family guide: Alagille syndrome is a rare genetic condition that can affect multiple parts of the body, most notably the liver and the heart. In people with this syndrome, the liver has fewer bile ducts than normal. Bile ducts are tubes that carry bile, a fluid that helps digest fats, from the liver to the gallbladder and small intestine. Because there are too few of these ducts, bile builds up in the liver, causing liver damage, yellowing of the skin and eyes (jaundice), and severe itching. The condition can also affect the eyes, though it usually does not cause severe vision loss. The most common eye feature is a harmless ring in the cornea called posterior embryotoxon, which a doctor can see during an eye exam. Some patients may also have changes in the retina or optic nerve. Additionally, Alagille syndrome can cause heart defects, kidney problems, differences in the bones of the spine, and distinct facial features like a broad forehead and a pointed chin. Because the symptoms can vary widely from person to person, even within the same family, treatment is tailored to each individual's specific needs. Management often involves a team of specialists to help with liver function, nutrition, and heart health. While there is no cure yet, treatments are available to help manage symptoms, improve bile flow, and ensure patients get the right nutrients to grow and thrive.

Symptoms and clinical features: Symptoms of Alagille syndrome typically appear in infancy and vary widely in severity. The most prominent symptoms are related to liver disease, including severe jaundice (yellowing of skin and eyes), intense pruritus (itching), dark urine, pale stools, and the development of xanthomas (cholesterol deposits under the skin). Due to poor fat absorption, infants often experience failure to thrive, poor growth, and signs of fat-soluble vitamin deficiencies (A, D, E, K). Cardiac symptoms may include heart murmurs, cyanosis, or signs of heart failure depending on the specific structural defect. Patients may also exhibit distinct facial features (broad forehead, deep-set eyes, pointed chin). While ocular symptoms are usually asymptomatic, some patients may experience mild visual disturbances if macular atrophy or retinal changes occur. Neurological symptoms can arise if vascular anomalies lead to strokes or bleeding.

Molecular pathology: Alagille syndrome is primarily caused by defects in the Notch signaling pathway, which is crucial for cell differentiation and development during embryogenesis. The vast majority of cases (over 94%) are due to pathogenic variants in the JAG1 gene, which encodes Jagged-1, a ligand for the Notch receptors. A smaller percentage of cases (about 2.5%) are caused by mutations in the NOTCH2 gene, which encodes the Notch2 receptor. The interaction between Jagged-1 and Notch2 is essential for the proper morphogenesis of various organs, particularly the biliary tree. In a healthy state, active Notch signaling promotes the expression of transcription factors that induce the differentiation of hepatocytes into bile duct cells and promote the formation of bile duct plates. Mutations in JAG1 or NOTCH2 disrupt this signaling pathway, leading to a failure in the proper development and maintenance of the intrahepatic bile ducts. This results in bile duct paucity, the hallmark of the hepatic manifestation of the disease. The defective Notch signaling also impairs the normal development of the heart, skeleton, kidneys, eyes, and vasculature, explaining the multisystemic nature of Alagille syndrome. The majority of JAG1 mutations result in a loss of function (haploinsufficiency), while NOTCH2 mutations are often missense variants.

Genetics: Alagille syndrome is inherited in an autosomal dominant pattern. It is caused by pathogenic variants in the JAG1 gene (accounting for approximately 94% of cases) or the NOTCH2 gene (accounting for about 2.5% of cases). The condition exhibits high penetrance but highly variable expressivity, meaning that even within the same family, affected individuals can have vastly different clinical presentations ranging from subclinical features to life-threatening liver or cardiac disease. About 30% to 50% of cases are inherited from an affected parent, while the remaining 50% to 70% result from de novo (new) mutations. Genetic counseling is recommended for affected individuals and their families. Prenatal testing and preimplantation genetic diagnosis are possible if the disease-causing mutation has been identified in the family. Due to the variable expressivity, predicting the severity of the disease in offspring based on the parent's phenotype is not possible.

Diagnostic evaluation: Diagnosis is established by the presence of at least three of the seven major clinical features (hepatic abnormalities, cardiac defects, renal dysfunction, skeletal abnormalities, ophthalmic findings, facial features, and vascular anomalies) or by the presence of bile duct paucity on liver biopsy along with two or more clinical features. Molecular genetic testing confirming a pathogenic variant in JAG1 or NOTCH2 provides definitive diagnosis, especially in individuals who do not meet full clinical criteria.

Differential diagnosis: Biliary atresia, alpha-1 antitrypsin deficiency, cystic fibrosis, progressive familial intrahepatic cholestasis, Zellweger syndrome, Noonan syndrome, William syndrome, Down syndrome, Axenfeld-Rieger syndrome

Natural history: The natural history of Alagille syndrome is highly variable. Liver disease typically presents within the first three months of life with jaundice and cholestasis. While some patients experience improvement in cholestasis as they age, 15% to 30% progress to end-stage liver disease requiring transplantation by age 5. Cardiac defects, present from birth, can range from benign murmurs to severe structural anomalies requiring early surgical intervention. Vascular anomalies, such as intracranial aneurysms, pose a lifelong risk for severe complications. Growth failure and fat-soluble vitamin deficiencies are common in childhood due to malabsorption.

Management and treatment research: ### Current management and supportive care Alagille syndrome can affect the liver, heart and blood vessels, kidneys, eyes, bones, and other body systems. Care is usually coordinated by a multidisciplinary team that may include liver specialists, cardiologists, nutrition specialists, kidney specialists, and other clinicians based on an individual’s needs. For cholestatic liver disease (reduced bile flow), care may include: - **Nutrition support:** High-calorie diets, medium-chain triglyceride (MCT) supplements, and monitoring for poor growth. - **Vitamin replacement:** Cholestasis can reduce absorption of fats and fat-soluble vitamins. Supplements of vitamins A, D, E, and K may be needed. - **Liver monitoring:** Regular assessment of liver function, growth, portal hypertension (increased pressure in blood vessels associated with the liver), and complications of chronic liver disease. - **Management of itching (pruritus):** Options may include ursodeoxycholic acid (UDCA), rifampin, cholestyramine, antihistamines, and other approaches selected by the care team. Response varies among individuals. For severe cholestasis or itching that does not improve with medicines, some people may be considered for procedures such as **partial external biliary diversion**, which changes how bile leaves the body. **Liver transplantation** may be needed for liver failure, serious complications of portal hypertension, or persistent severe itching that substantially affects quality of life. Heart and blood-vessel abnormalities may require monitoring, medicines, catheter-based procedures, or surgery. Kidney, eye, skeletal, developmental, and other concerns should also be monitored and treated as needed. ### Approved therapies for cholestatic pruritus Two oral ileal bile acid transporter (IBAT) inhibitors are approved in the United States for itching associated with Alagille syndrome. IBAT inhibitors reduce reabsorption of bile acids in the intestine, which may lower the amount of bile acids circulating in the body. - **Maralixibat (Livmarli):** Approved for cholestatic pruritus in people with Alagille syndrome aged 3 months and older. - **Odevixibat (Bylvay):** Approved for pruritus in people with Alagille syndrome aged 12 months and older. These medicines may reduce itching for some people, but they do not correct the genetic cause of Alagille syndrome. Diarrhea and other gastrointestinal effects can occur. Care teams may monitor liver tests, growth, nutrition, and vitamin levels during treatment. ### Investigational therapies There are no condition-specific investigational treatment programs listed in the current treatment pipeline. Research continues to evaluate the long-term safety and effectiveness of available treatments and to improve understanding of the natural history of Alagille syndrome. ### Clinical trial participation Clinical studies and registries can help researchers better understand Alagille syndrome and assess treatments over time. Current listed studies include: - **NCT05035030:** A Phase 3 long-term safety and efficacy study of odevixibat in people with Alagille syndrome. This study is active but not recruiting. - **NCT01793168:** Rare Disease Patient Registry & Natural History Study—Coordination of Rare Diseases at Sanford. This registry study is recruiting. Eligibility may depend on age, symptoms, previous treatments, and location. A care team can help families discuss whether participation in a registry or clinical study may be appropriate.

Outlook: The prognosis for Alagille syndrome depends heavily on the severity of liver and cardiac involvement. Overall mortality is estimated at around 8.5%, with most deaths occurring in the first five years of life due to complex cardiac disease, severe liver disease, or intracranial bleeding. Up to 75% of patients with severe hepatic involvement may require a liver transplant by age 18, after which survival rates are high. Visual prognosis is generally favorable, as the common ocular findings rarely cause significant vision loss.

Epidemiology: Alagille syndrome is a rare genetic disorder with an estimated prevalence ranging from 1 in 30,000 to 1 in 100,000 live births. It affects males and females equally and occurs across all ethnic and racial groups. The true prevalence may be higher due to variable expressivity, leading to underdiagnosis in individuals with mild or subclinical manifestations.

Selected references: 1. Turnpenny PD, Ellard S. Alagille syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet. 2012. 2. Gilbert MA, Bauer RC, Rajagopalan R, et al. Alagille syndrome mutation update: Comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification. Hum Mutat. 2019. 3. Emerick KM, Rand EB, Goldmuntz E, et al. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology. 1999. 4. Kamath BM, Loomes KM, Piccoli DA. Medical management of Alagille syndrome. J Pediatr Gastroenterol Nutr. 2010. 5. Vandriel SM, Li LT, She H, et al. Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study. Hepatology. 2023.